Repligen
RGEN
#2377
Rank
โ‚ฌ6.91 B
Marketcap
122,53ย โ‚ฌ
Share price
-4.93%
Change (1 day)
15.53%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of March 2026 : โ‚ฌ0.60 Billion

According to Repligen 's latest financial reports the company's total debt is โ‚ฌ0.60 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2026)

Total debt by year

Year Total debt Change
2025-12-31โ‚ฌ0.58 B-10.94%
2024-12-31โ‚ฌ0.65 B2.42%
2023-12-31โ‚ฌ0.64 B63.3%
2022-12-31โ‚ฌ0.39 B21.99%
2021-12-31โ‚ฌ0.32 B44.35%
2020-12-31โ‚ฌ0.22 B-4.74%
2019-12-31โ‚ฌ0.23 B159.84%
2018-12-31โ‚ฌ90.46 M9.36%
2017-12-31โ‚ฌ82.71 M-8.67%
2016-12-31โ‚ฌ90.57 M
2005-03-31โ‚ฌ0.09 M34.1%
2004-03-31โ‚ฌ0.06 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
โ‚ฌ55.87 B 9,168.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
โ‚ฌ37.83 B 6,176.87%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
โ‚ฌ17.77 B 2,848.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ40.70 B 6,651.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
โ‚ฌ22.28 M-96.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
โ‚ฌ0.25 B-57.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
โ‚ฌ0.35 B-40.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
โ‚ฌ0.25 B-57.78%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
โ‚ฌ1.26 B 109.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
โ‚ฌ2.67 B 344.47%๐Ÿ‡บ๐Ÿ‡ธ USA